Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(50%)

Phase Distribution

Ph not_applicable
1
50%
Ph early_phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (50.0%)
N/A1 (50.0%)

Trials by Status

completed150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
completednot_applicable

Image-Guided Stereotactic Biopsy of High Grade Gliomas

NCT00979810
terminatedearly_phase_1

An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs

NCT00414570

Clinical Trials (2)

Showing 2 of 2 trials
NCT00979810Not Applicable

Image-Guided Stereotactic Biopsy of High Grade Gliomas

Completed
NCT00414570Early Phase 1

An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2